Business Description
Neuronetics Inc
NAICS : 325413
SIC : 3845
ISIN : US64131A1051
Total Employee Number:
658Description
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 6.44 | |||||
Debt-to-EBITDA | -3.28 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.08 | |||||
Beneish M-Score | -3.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.3 | |||||
3-Year EBITDA Growth Rate | 29 | |||||
3-Year EPS without NRI Growth Rate | 24.7 | |||||
3-Year FCF Growth Rate | 36.7 | |||||
3-Year Book Growth Rate | -46.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.13 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.92 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.61 | |||||
9-Day RSI | 63.12 | |||||
14-Day RSI | 57.41 | |||||
3-1 Month Momentum % | -15.57 | |||||
6-1 Month Momentum % | -8.32 | |||||
12-1 Month Momentum % | -64.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.67 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 0.48 | |||||
Days Inventory | 20.7 | |||||
Days Sales Outstanding | 49.72 | |||||
Days Payable | 48.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.3 | |||||
Shareholder Yield % | -26.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.96 | |||||
Operating Margin % | -19.4 | |||||
Net Margin % | -24.48 | |||||
EBITDA Margin % | -17.19 | |||||
FCF Margin % | -9.02 | |||||
OCF Margin % | -8.5 | |||||
ROE % | -147.75 | |||||
ROA % | -26.93 | |||||
ROIC % | -28.54 | |||||
3-Year ROIIC % | 6.95 | |||||
ROC (Joel Greenblatt) % | -66.97 | |||||
ROCE % | -26.76 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.63 | |||||
PB Ratio | 7.38 | |||||
EV-to-EBIT | -5.92 | |||||
EV-to-EBITDA | -6.67 | |||||
EV-to-Revenue | 1.15 | |||||
EV-to-Forward-Revenue | 1.06 | |||||
EV-to-FCF | -12.8 | |||||
Price-to-GF-Value | 0.72 | |||||
Earnings Yield (Greenblatt) % | -16.89 | |||||
FCF Yield % | -13.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Neuronetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 130.298 | ||
| EPS (TTM) (€) | -0.464 | ||
| Beta | 3.0956 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 100.49 | ||
| 14-Day RSI | 57.41 | ||
| 14-Day ATR (€) | 0.052578 | ||
| 20-Day SMA (€) | 1.086 | ||
| 12-1 Month Momentum % | -64.78 | ||
| 52-Week Range (€) | 0.988 - 3.94 | ||
| Shares Outstanding (Mil) | 69.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuronetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuronetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 123 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 32 days | ||
| General meeting for 2026 | 2026-05-28 08:00 | 1.04 (+2.46%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:30 | 1.67 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1.67 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-17 08:30 | 1.16 (+1.22%) | ||
| Annual report for 2025 | 2026-03-17 | 1.16 (+1.22%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 1.16 (+1.22%) |
Show
Entries
Neuronetics Inc Frequently Asked Questions
What is Neuronetics Inc(FRA:NRC)'s stock price today?
The current price of FRA:NRC is €1.20. The 52 week high of FRA:NRC is €3.94 and 52 week low is €0.99.
When is next earnings date of Neuronetics Inc(FRA:NRC)?
The next earnings date of Neuronetics Inc(FRA:NRC) is 2026-08-05 Est..
Does Neuronetics Inc(FRA:NRC) pay dividends? If so, how much?
Neuronetics Inc(FRA:NRC) does not pay dividend.
Press Release
Articles on Neuronetics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers